7516

Sea Mild BiotechnologyTPEX:7516 Stock Report

Market Cap

NT$152.5m

7D

-0.3%

1Y

-49.1%

Updated

19 Sep, 2021

Data

Company Financials
7516 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

7516 Overview

Sea Mild Biotechnology Co., Ltd. manufactures and sells multi-purpose natural lotions based on sea salt in Taiwan.

Price History & Performance

Summary of all time highs, changes and price drops for Sea Mild Biotechnology
Historical stock prices
Current Share PriceNT$7.90
52 Week HighNT$7.13
52 Week LowNT$15.73
Beta0.16
1 Month Change1.67%
3 Month Change-13.09%
1 Year Change-49.14%
3 Year Changen/a
5 Year Changen/a
Change since IPO-80.71%

Recent News & Updates

Shareholder Returns

7516TW Household ProductsTW Market
7D-0.3%-4.5%-1.1%
1Y-49.1%-26.0%33.6%

Return vs Industry: 7516 underperformed the TW Household Products industry which returned -26% over the past year.

Return vs Market: 7516 underperformed the TW Market which returned 33.6% over the past year.

Price Volatility

Is 7516's price volatile compared to industry and market?
7516 volatility
7516 Beta0.16
Industry Beta0.43
Market Beta1

Stable Share Price: 7516 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 7516's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/an/ahttps://www.seamild.com.tw

Sea Mild Biotechnology Co., Ltd. manufactures and sells multi-purpose natural lotions based on sea salt in Taiwan. It offers cleaning products for clothing, home, and personal cleaning, as well as other commercial specifications under the Sea Mild brand name. The company also exports its products.

Sea Mild Biotechnology Fundamentals Summary

How do Sea Mild Biotechnology's earnings and revenue compare to its market cap?
7516 fundamental statistics
Market CapNT$152.54m
Earnings (TTM)-NT$72.76m
Revenue (TTM)NT$151.55m

1.0x

P/S Ratio

-2.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
7516 income statement (TTM)
RevenueNT$151.55m
Cost of RevenueNT$143.68m
Gross ProfitNT$7.87m
ExpensesNT$80.62m
Earnings-NT$72.76m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-3.77
Gross Margin5.19%
Net Profit Margin-48.01%
Debt/Equity Ratio0%

How did 7516 perform over the long term?

See historical performance and comparison

Valuation

Is Sea Mild Biotechnology undervalued compared to its fair value and its price relative to the market?

1.44x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 7516's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 7516's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 7516 is unprofitable, so we can't compare its PE Ratio to the TW Household Products industry average.

PE vs Market: 7516 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 7516's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 7516 is good value based on its PB Ratio (1.4x) compared to the TW Household Products industry average (2.1x).


Future Growth

How is Sea Mild Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

12.4%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sea Mild Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Sea Mild Biotechnology performed over the past 5 years?

-49.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 7516 is currently unprofitable.

Growing Profit Margin: 7516 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 7516 is unprofitable, and losses have increased over the past 5 years at a rate of 49.3% per year.

Accelerating Growth: Unable to compare 7516's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 7516 is unprofitable, making it difficult to compare its past year earnings growth to the Household Products industry (26%).


Return on Equity

High ROE: 7516 has a negative Return on Equity (-68.52%), as it is currently unprofitable.


Financial Health

How is Sea Mild Biotechnology's financial position?


Financial Position Analysis

Short Term Liabilities: 7516's short term assets (NT$115.7M) exceed its short term liabilities (NT$58.9M).

Long Term Liabilities: 7516's short term assets (NT$115.7M) exceed its long term liabilities (NT$20.7M).


Debt to Equity History and Analysis

Debt Level: 7516 is debt free.

Reducing Debt: 7516 has no debt compared to 5 years ago when its debt to equity ratio was 73.6%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 7516 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 7516 has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 4% each year.


Dividend

What is Sea Mild Biotechnology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 7516's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 7516's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 7516's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 7516's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 7516's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Sea Mild Biotechnology has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sea Mild Biotechnology Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Sea Mild Biotechnology Co., Ltd.
  • Ticker: 7516
  • Exchange: TPEX
  • Founded: NaN
  • Industry: Household Products
  • Sector: Household
  • Market Cap: NT$152.541m
  • Shares outstanding: 19.31m
  • Website: https://www.seamild.com.tw

Number of Employees


Location

  • Sea Mild Biotechnology Co., Ltd.
  • No. 43, Guanye East Road
  • Pingzhen District
  • Taoyuan
  • 324
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/19 08:35
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.